Understanding NINLARO®

Ninlaro® (ixazomib) is the first oral proteasome inhibitor approved by the FDA to treat myeloma. Ninlaro is the third drug in the proteasome inhibitor class that has been approved for myeloma. It is indicated for myeloma patients who have received at least one prior therapy.

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.